The unfinished legacy of liver transplantation: Emphasis on immunology

Hepatology

Volumn 43, Issue 2 SUPPL. 1, 2006, Pages

  Starzl, Thomas E ^a,b   Lakkis, Fadi G ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; GROWTH FACTOR; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INSULIN; PREDNISONE; PROTEINASE INHIBITOR; TSUKUBAENOLIDE; ZIDOVUDINE;

AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DISEASE SURVEILLANCE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INBORN ERROR OF METABOLISM; LIVER FUNCTION; LIVER SIZE; LIVER STRUCTURE; LIVER TRANSPLANTATION; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; PARASITOSIS; PRIORITY JOURNAL; REGENERATION; REVIEW; VIRUS INFECTION;

ANIMALS; GRAFT VS HOST REACTION; HEPATITIS C, CHRONIC; HOST VS GRAFT REACTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; TRANSPLANTATION CHIMERA; TRANSPLANTATION IMMUNOLOGY;

EID: 33644512797     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20959     Document Type: Review

References (157)

1. Welch CS. A note on transplantation of the whole liver in dogs. Transplant Bull 1955;2:54-55.
2. Cannon JA: Brief report. Transplant Bull 1956;3:7.
3. Starzl TE, Kaupp HA Jr, Brock DR, Lazarus RE, Johnson RV. Reconstructive problems in canine liver homotransplantation with special reference to the postoperative role of hepatic venous flow. Surg Gynecol Obstet 1960;111:733-743.
4. Moore KD, Wheeler HB, Demissianos HV, Smith LL, Balankura O, Abel K, et al. Experimental whole organ transplantation of the liver and of the spleen. Ann Surg 1960;152:374-387.
5. Starzl TE, Kaupp HA Jr. Mass homotransplantation of abdominal organs in dogs. Surg Forum 1960;11:28-30.
6. Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963;117:385-395.
7. Marchioro TL, Huntley RT, Waddell WR, Starzl TE. Extracorporeal perfusion for obtaining postmortem homografts. Surgery 1963;54:900-911.
8. Starzl TE, Marchioro TL, Von Kaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963;117:659-676.
9. Starzl TE, Marchioro TL, Rowlands DT Jr, Kirkpatrick CH, Wilson WEC, Rifkind D, et al. Immunosuppression after experimental and clinical homotransplantation of the liver. Ann Surg 1964;160:411-439.
10. Marchioro TL, Porter KA, Dickinson TC, Faris TD, Starzl TE. Physiologic requirements for auxiliary liver homotransplantation. Surg Gynecol Obstet 1965;121:17-31.
11. Starzl TE, Marchioro TL, Porter KA, Taylor PD, Faris TD, Herrmann TJ, et al. Factors determining short- and long-term survival after orthotopic liver homotransplantation in the dog. Surgery 1965;58:131-155.
12. Starzl TE. Orthotopic heterotransplantation. In: Starzl TE, ed. Experience in Hepatic Transplantation. Philadelphia: WB Saunders, 1969:408-421.
13. Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, Cerilli GJ. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet 1967;124:301-318.
14. Terasaki PI, Vredevoe DL, Mickey MR, Porter KA, Marchioro TL, Faris TD, et al. Serotyping for homotransplantation. VI. Selection of kidney donors for thirty-rwo recipients. Ann NY Acad Sci 1966;129:500-520.
15. Starzl TE, Porter KA, Andres G, Halgrimson CG, Hurwitz R, Giles G, et al. Long-term survival after renal transplantation in humans: With special reference to histocompatibility matching, thymectomy, homograft glomerolonephritis, heterologous ALG, and recipient malignancy. Ann Surg 1970;172:437-472.
16. Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, Moon JB, et al. Orthotopic homotransplantation ot the human liver. Ann Surg 1968;168:392-415.
17. Definition of irreversible coma: report of the ad hoc committee of the Harvard Medical School to examine the definition of brain death. JAMA 1968;205:337.
18. Cordier G, Garnier H, Clot JP, Campiez P, Gorin JP, Clot Ph, et al. La greffe de foie orthotopique chez le porc. Mem Acad Chir (Paris) 1966;92:799-807.
19. Peacock JH, Terblanche J. Orthotopic homotransplantation of the liver in the pig. In: Read AE, ed. The Liver. London: Butterworth, 1967:333.
20. Calne RY, White HJO, Yoffa DE, Binns RM, Maginn RR, Herbertson RM, et al. Prolonged survival of liver transplants in the pig. Br Med J 1967;4:645-648.
21. Starzl TE (with the assistance of Putnam CW). Experience in Hepatic Transplantation. Philadelphia: WB Saunders, 1969:1-533.
22. DuBois RS, Giles G, Rodgerson DO, Lilly J, Martineau C, Halgrimson CG, et al. Orthotopic liver transplantation for Wilson s disease. Lancet 1071;1:505-508.
23. Starzl TE, Chase HP, Putnam CW, Porter KA. Portacaval shunt in hyperlipoproteinemia. Lancet 1973;2:940-944.
24. Starzl TE, Lee IY, Porter KA, Putnam CW. The influence of portal blood upon lipid metabolism in normal and diabetic dogs and baboons. Surg Gynecol Obstet 1975;140:381-396.
25. Starzl TE, Chase HP, Ahrens EH Jr, McNamara DJ, Bilheimer DW, Schaefer EJ, et al. Portacaval shunt in patients with familial hypercholesterolemia. Ann Surg 1983;198:273-283.
26. Starzl TE. The little drummer girls. In: The Puzzle People. Pittsburgh: University of Pittsburgh Press, 1992:318-333.
27. Brown MS, Golstein JL. Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic. J Clin Invest 1983;72:743-747.
28. Starzl TE, Ishikawa M, Putnam CW, Porter KA, Picache R, Husberg BS, et al. Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc 1974;6:129-139.
29. Starzl TE, Francavilla A, Halgrimson CG, Francavilla FR, Porter KA, Brown TH, et al. The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet 1973;137:179-199.
30. Starzl TE, Porter KA, Putnam CW. Intraportal insulin protects from the liver injury of portacaval shunt in dogs. Lancet 1975;2:1241-1246.
31. Starzl TE, Porter KA, Putnam CW, Schroter GPJ, Halgrimson CG, Weil R III, et al. Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet 1976;142:487-505.
32. Wall WJ, Calne RY, Herbertson BM, Baker PG, Smith DP, Underwood J, et al. Simple hyptothermic preservation for transporting human livers long distance for homotransplantation. Transplantation 1977;23:210-216.
33. Benichou J, Halgrimson CG, Weil R III, Koep LJ, Starzl TE. Canine and human liver preservation for 6 to 18 hour by cold infusion. Transplantation 1977;24:407-411.
34. Starzl TE, Halgrimson CG, Koep LJ, Weil R III, Taylor PD. Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet 1979;149:737.
35. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979;2:1033-1036.
36. Starzl TE, Weil R III, Iwatsuki S, Klintmalm G, Schroter GPJ, Koep LJ, et al. The use or cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet 1980;151:17-26.
37. Starzl TE, Klintmalm GBG, Porter KA, Iwatsuki S, Schroter GPJ. Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 1981;305:266-269.
38. Starzl TE, Iwatsuki S, Van Thiel DH, Gartner JC, Zitelli BJ, Malatack JJ, et al. Evolution of liver transplantation. HEPATOLOGY 1982;2:614-636.
39. Denmark SW, Shaw BW Jr, Starzl TE, Griffith BP. Veno-venous bypass without systemic anticoagulation in canine and human liver transplantation. Surg Forum 1983;34:380-382.
40. Shaw BW Jr, Martin DJ, Marquez JM, Kang YG, Bugbee AC, Iwatsuki S, et al. Venous bypass in clinical liver transplantation. Ann Surg 1984;200:524-534.
41. Griffith BP, Shaw BW Jr, Hardesty RL, Iwatsuki S, Bahnson HT, Starzl TE. Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg Gynecol Obstet 1985;160:270-272.
42. National Institutes of Health Consensus Development Conference on Liver Transplantation. Sponsored by the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases and the National Institutes of Health Office of Medical Applications of Research. HEPATOLOGY 1984;4(1 Suppl):1S-110S.
43. Starzl TE, Hakala TR, Shaw BWJr, Hardesty RL, Rosenthal TJ, Griffith BP, et al. A flexible procedure for multiple cadavetic organ procurement. Surg Gynecol Obstet 1984;158:223-230.
44. Starzl TE, Miller C, Broznick B, Makowka L. An improved technique for multiple organ harvesting. Surg Gynecol Obstet 1987;165:343-348.
45. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;1:583-587.
46. Bismuth H, Houssin D. Reduced-sized orthotopic liver graft in hepatic-transplantation in children. Surgery 1984;95:367-370.
47. Broelsch CE, Neuhaus P, Burdelski M, Berngau U, Pichlmayr R. Orthotope transplantation von Lebegmenten bei mit Gallengangsatresien. (Orthotopic transplantation of hepatic segments in infants with biliary atresia). In: Kolsowski L, ed. Chirurgisches Forum 1984, F Experim U Klimische Forschung Hrsga. Berlin: Springer-Verlag, 1984:105-109.
48. Starzl TE, Bilheimer DW, Bahnson HT, Shaw BW Jr, Hardesty RL, Griffith BP, et al. Heart-liver transplantation in a patient with familial hypercholesterolemia. Lancet 1984;1:1382-1383.
49. Bilheimer DW, Goldstein JL, Grundy SC, Starzl TE, Brown MS. Liver transplantation provides low-density-lipoprotein receptors and lowers plasma cholesterol in a child with homozygous familial hypercholesterolemis. N Engl J Med 1984;311:1658-1664.
50. Starzl TE, Rowe MI, Todo S, Jaffe R, Tzakis A, Hoffman AL, et al. Transplantation of multiple abdominal viscera. JAMA 1989;261:1449-1457.
51. Grant D, Wall W, Mimeault R, Zhong R, Ghent C, Garcia B, et al. Successful small-bowel/liver transplantation. Lancet 1990;335:181-184.
52. Jamieson NV, Sundberg R, Lindell S, Laravuso M, Kalayoglu M, Southard JH, et al. Successful 24- to 30-hour preservation of the canine liver: a preliminary report. Transplant Proc 1988;20(Suppl. 1):945-947.
53. Kalayoglu M, Sollinger HW, Stratta RJ, D'Alessandro AM, Hoffmann RM, Pirsch JD, et al. Extended preservation of the liver for clinical transplantation. Lancet 1988;1:617-619.
54. Todo S, Nery J, Yanaga K, Podesta L, Gordon RD, Starzl TE. Extended preservation of human liver grafts with UW solution. JAMA 1989;261:711-714.
55. Makowka L, Gordon RD, Todo S, Ohkohchi N, MarshJW, Tzakis AG, et al. Analysis of donor criteria for the prediction of outcome in clinical liver transplantation. Transplant Proc 1987;19:2378-2382.
56. Starzl TE, Hakala T, Tzakis A, Gordon R, Stieber A, Makowka L, et al. A multifactorial system for equitable selection of cadaveric kidney recipients. JAMA 1987;257:3073-3075.
57. Starzl TE, Gordon RD, Tzakis A, Staschak S, Fioravanti V, Broznick B, et al. Equitable allocation of extrarenal organs: With special reference to the liver. Transplant Proc 1988;20:131-138.
58. Tzakis A, Todo S, Starzl TE. Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg 1989;210:649-652.
59. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A. FK 506 for human liver, kidney and pancreas transplantation. Lancet 1989;2:1000-1004.
60. Todo S, Fung JJ, Starzl TE, Tzakis A, Demetris AJ, Kormos R, et al. Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 1990;212:295-305.
61. Pichlmayr R, Ringe B, Gubernatis G, Hauss J, Bunzendahl H. Transplantation einer spenderleber auf Zwis Empfanger (Split liver transplantation) Eine neue methode in der weitzentwicklung der lebesegment transplantation. Langenbecks Arch Chir 1988;373:127-130.
62. Strong RW, Lynch SV, Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver transplantation from a living donor to her son. N Engl J Med 1990;322:1505-1507.
63. Broelsch CE, Emond JC, Whitington PF, Thistlethwaite JR, Baker AL, Lichtor JL. Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts, and living related segmental transplants. Ann Surg 1990;212:368-375.
64. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet 1992;339:1579-1582.
65. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. HEPATOLOGY 1993;17:1127-1152.
66. Starzl TE, Zinkernagel R. Antigen localization and migration in immunity and tolerance. N Engl J Med 1998;339:1905-1913.
67. Yamaoka Y, Washida M, Honda K, Tanaka K, Mori K, Shimahara Y, et al. Liver transplantation using a right lobe graft from a living related donor. Transplantation 1994;57:1127-1130.
68. Wachs M, Bak T, Karrer F, Everson GT, Shrestha R, Trouillot TE, et al. Adult living donor liver transplantation using a right hepatic lobe. Transplantation 1998;66:1313-1316.
69. Marcos A, Fisher RA, Ham JM, Shiffman ML, Sanyal AJ, Luketic VA, et al. Right lobe living donor liver transplantation. Transplantation 1999;68:798-803.
70. Starzl TE, Zinkernagel R. Transplantation tolerance from a historical perspective. Nature Reviews: Immunology 2001;1:233-239.
71. Phelps CJ, Koike C, Vaught TD, Boone J, Wells KD, Chen SH, et al. Production of α1,3-galactosyltransferase-deficient pigs. Science 2003;299:411-414.
72. Starzl TE, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003;361:1502-1510.
73. Eghtesad B, Fung JJ, Demetris AJ, Murase N, Ness R, Bass DC, et al. Mechanism-based principles of immunosuppression for liver transplantation in HCV-infected patients. Liver Transpl 2005;11:1343-1352.
74. Anonymous. Action Plan for Liver Disease Research. In: National Institutes of Health, NIH Pub. No. 04-5491, U.S. Department of Health and Human Services, 2004 (December):1-93.
75. Francavilla A, Hagiya M, Porter KA, Polimeno L, Ihara I, Starzl TE. Augmenter of liver regeneration (ALR): its place in the universe of hepatic growth factors. HEPATOLOGY 1994;20:747-757.
76. Starzl TE, Porter KA, Kashiwagi N, Lee IY, Russell WJI, Putnam CW. The effect of diabetes mellitus on portal blood hepatotrophic factors in dogs. Surg Gynecol Obstet 1975;140:549-562.
77. Starzl TE, Porter KA, Kashiwagi N, Putnam CW. Portal hepatotrophic factors, diabetes mellitus and acute liver atrophy, hypertrophy and regeneration. Surg Gynecol Obstet 1975;141:843-858.
78. Starzl TE, Demetris AJ, Van Thiel DH. Medical progress: liver transplantation. N Engl J Med [Part I] 1989;321:1014-1022;
79. N Engl J Med [Part II] 1989;321:1092-1099.
80. Wolstenholme GEW, O'Connor M (eds). Ethics in Medical Progress: With Special Reference to Transplantation. Boston: Little, Brown, 1966:1-249. The Symposium held in London at the CIBA House was attended by 25 invited physicians and surgeons (including TES, Keith Reemtsma, and Joseph E. Murray), ethicists, religious leaders, medical philosophers, judges, and lawyers.
81. Burger WF. The law and medical advances. Ann Intern Med 1967;67(Suppl 7):15-18 Symposium on Medical Ethics of the American Association of Physicians with presentations by: Peter Medawar, Joshua Lederburg, Thomas Starzl, and Warren Burger (subsequently Chief Justice of the United States Supreme Court).
82. Medawar PB. The behavior and fate of skin autografts and skin homografts in rabbits. J Anat 1944;78:176-199.
83. Owen RD. Immunogenetic consequences of vascular anastomoses beween bovine twins. Science 1945;102:400-401.
84. Billingham RE, Brent L, Medawar PB. "Actively acquired tolerance" of foreign cells. Nature 1953;172:603-606.
85. Main JM, Prehn RT. Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst 1955;15:1023-1029.
86. Murray JE, Merrill JP, Dammin GJ, Dealy JB, Jr., Walter CW, Brooke MS, et al. Study of transplantation immunity after total body irradiation: clinical and experimental investigation. Surgery 1960;48:272-284.
87. Hamburger J, Vaysse J, Crosnier J, Tubiana M, Lalanne CM, Antoine B, et al. Transplantation of a kidney between nonmonozygotic twins after irradiation of the receiver. Good function at the fourth month. Presse Med 1959;67:1771-1775.
88. Hamburger J, Vaysse J, Crosnier J, Auvert J, Lalanne CL, Hopper J, Jr. Renal homotransplantation in man after radiation of the recipient. Am J Med 1962;32:854-871.
89. Kuss R, Legrain M, Mathe G, Nedey R, Camey M. Homologous human kidney transplantation: experience with six patients. Postgrad Med J 1962;38:528-531.
90. Calne RY. Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant Bull 1961;28:445-461.
91. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963;268:1315-1323.
92. Hopewell J, Calne RY, Beswick I. Three clinical cases of renal transplantation. Br Med J 1964;1:411-413.
93. Slavin S, Strober S, Fuks Z, Kaplan HS. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med 1977;146:34-48.
94. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone matrow leads to specific acceptance of allografts or xenografts. Nature 1984;307:168-170.
95. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989;169:493-502.
96. Colson YL, Li H, Boggs SS, Patrene KD, Johnson PC, Ildstad ST. Durable mixed allogeneic chimerism and tolerance by a non-lethal radiation-based cytoreductive approach. J Immunol 1996;157:2820-2829.
97. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997;89:3048-3054.
98. Thomas JM, Eckhoff DE, Contreras JL, Lobashevsky AL, Hubbard WJ, Moore JK, et al. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin. Transplantation 2000;69:2497-2503.
99. Wekerle T, Sykes M. Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation 1999;68:459-467.
100. Cosimi AB, Sachs DH. Mixed chimerism and transplantation tolerance. Transplantation 2004;77:943-946.
101. Starzl TE, Demetris AJ, Trucco M, Ramos H, Zeevi A, Rudert WA, et al. Systemic chimerism in human female recipients of male livers. Lancet 1992;340:876-877
102. Starzl TE, Demetris AJ, Trucco M, Ricordi C, Ildstad S, Terasaki PI, et al. Chimerism after liver transplantation for type IV glycogen storage disease and Type I Gaucher's disease. N Engl J Med 1993;328:745-749.
103. Starzl TE, Demetris AJ, Trucco M, Zeevi A, Ramos H, Terasaki P, et al. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993;55:1272-1277.
104. Starzl TE, Demetris AJ. Transplantation milestones: viewed with one- and two-way paradigms of tolerance. JAMA 1995;273:876-879.
105. Przepiorka D, Thomas ED, Durham DM, Fisher L. Use of a probe to repeat sequence of the Y chromosome for detection of host cells in peripheral blood of bone marrow transplant recipients. Am J Clin Pathol 1991;95:201-206.
106. Schlitt HJ, Hundrieser J, Ringe B, Pichlmayr R. Donor-type microchimerism associated with graft rejection eight years after livet transplantation. N Engl J Med 1994;330:646-647.
107. Burlingham WJ, Grailer AP, Fechner JH, Kusaka S, Trucco M, Kocova M, et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 1995;59:1147-1155.
108. Wood K, Sachs DH. Chimerism and transplantation tolerance, cause and effect. Immunol Today 17 1996;12:584-588.
109. Bushell A, Pearson TC, Morris PJ, Wood KJ. Donor-recipient microchimerism and tolerance induction. Transplantation 1996;61:170-172.
110. Miller J, Mathew JM, Esquenazi V. Toward tolerance to human organ transplants, a few additional corollaries and questions. Transplantation 2004;77:940-942.
111. Ko S, Deiwick A, Jager MD, Dinkel A, Rohde F, Fischer R, et al. The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat. Nature Med 1999;5:1292-1297.
112. Zinkernagel RM. Restriction by H-2 gene complex ot transfer of cell-mediated immunity to Listeria monocytogenes. Nature 1974;251:230-233.
113. Doherty PC, Zinkernagel RM. A biological role for the major histocompatibility antigens. Lancet 1975:1406-1409.
114. Zinkernagel RM, Doherty PC. The discovery of MHC restriction. Immunol Today 1997;18:14-17.
115. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-761.
116. Zinkernagel RM, Moskophidis D, Kundig T, Oehen S, Pircher H, Hengartner H. Effector T-cell induction and T-cell memory versus peripheral deletion of T cells. Immunol Rev 1993;131:199-223.
117. Starzl TE. Rejection in unmodified animals. In: Experience in Hepatic-Transplantation. Philadelphia: W.B. Saunders, 1969:184.
118. Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM. Induction of immunological tolerance by porcine liver allografts. Nature 1969;223:472-474.
119. Kamada N, Brons G, Davies HffS. Fully allogeneic liver grafting in rats induces a state of systemic nonreactivity to donor transplantation antigens. Transplantation 1980;29:429-431.
120. Zimmerman FA, Davies HS, Knoll PP, Gocke JM, Schmidt T. Orthotopic liver allografts in the rat. Transplantation 1984;37:406-410.
121. Murase N, Starzl TE, Tanabe M, Fujisaki S, Miyazawa H, Ye Q, et al. Variable chimerism, graft versus host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to Brown-Norway rats. Transplantation 1995;60:158-171.
122. Qian S, Demetris AJ, Murase N, Rao AS, Fung JJ, Starzl TE. Murine liver allograft transplantation: tolerance and donor cell chimerism. HEPATOLOGY 1994;19:916-924.
123. Corry RJ, Winn HJ, Russell PS. Primary vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973;16:343-350.
124. Russell PS, Chase CM, Colvin RB, Plate JMD. Kidney transplants in mice: an alalysis of the immune status of mice bearing long-term H-2 incompatible transplants. J Exp Med 1978;147:1449-1468.
125. Wang C, Sun J, Sheil AG, McCaughan GW, Bishop GA. A short course of methylprednisolone immunosuppression inhibits both rejection and spontaneous acceptance of rat liver allografts. Transplantation 2001;72:44-51.
126. κB: implications for tolerance induction. Transplantation 2000;70:415-419.
127. Larsen CP, Elwood ET, Alexander DZ, Ritchie Sc, Hendrix R, Tucker-Burden C, te al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.
128. Myburgh JA. Total lymphoid irradiation in transplantation: experimental background and results in 70 patients. In: Messmer K, Stein M. Pathways in Applied Immunology. Berlin: Springer-Verlag, 1991:87-93.
129. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999;5:686-693.
130. Zinkernagel RM, Hengarrner H. T-cell mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol Today 1994;15:262-268.
131. Shapiro R, Jordan M, Basu A, Scantlebury V, Potdar S, Tan H, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression, with subsequent weaning. Ann Surg 2003;238:520-527.
132. Shapiro R, Basu A, Tan H, Gray E, Kahn A, Randhawa P, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or campath. J Am Coll Surg 2005;200:505-515.
133. McCurry K, Iacano A, Zeevi A, Yousem S, Zaldonis D, Girnita A, et al. Early outcomes in human lung transplantation utilizing thymoglobulin or campath 1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005;130:528-537.
134. Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, deVera M, et al. Use of alemruzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004;78:966-971.
135. Curry MP. Hepatitis B and Hepatitis C viruses in liver transplantation. Transplantation 2004;78:955-963.
136. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. HEPATOLOGY 2003;38:34-41.
137. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004;77:226-231.
138. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. In: Wiesner RH, Sorrell MF, Villamil F, International Liver Transplantation Society Experts Panel, eds. Liver Transplantation and Hepatitis C. A Single Topic and Consensus Development Symposium. Liver Transpl 2003;9(Suppl3):S1-S119.
139. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. HEPATOLOGY 2002;36:202-210.
140. Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. HEPATOLOGY 2005;41:832-835.
141. Starzl TE. Late results and complications. In: Experience in Hepatic Transplantation. Philadelphia: WB Saunders, 1969:348-393.
142. Starzl TE, Penn I, Putnam CW, Groth CG, Halgrimson CG. Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy. Transplant Rev 1971;7:112-145.
143. Coggin JH, Larson VM, Hilleman MR. Prevention of SV40 virus tumorigenesis by irradiated, disrupted and iododeoxyuridine treated tumor cell antigens. Proceedings of the Society for Experimental Biology and Medicine 1967;124:774-784.
144. Hilleman MR. Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology. Immunol Rev 1999;170:7-27.
145. Bachmann MF, Hunziker L, Zinkernagel RM, Storni T, Kopf M. Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key. Eur J Immunol 2004;34:317-326.
146. Klenerman P. Commentary: T cells get by with a little help from their friends. Eur J Immunol 2004;34:313-316.
147. Ehrlich P, Morgenroth J. Über Hämolysine. Fünfte Mittheilung Berl. Klin. Wschr. 1901;38:598-604.
148. Reproduced in (1957) The Collected Papers of Paul Ehrlich, ed. Himmelweit, F. London: Pergamon, Vol 2. pp. 234-245 (with English translation pp. 246-255).
149. Frey JR, Wenk P. Experimental studies on the pathogenesis of contact eczema in the guinea pig. Int Arch Allergy Appl Immunol 1957;11:81-100.
150. Barker CF, Billingham RE. The role of afferent lymphatics in the rejection of skin homografts. J Exp Med 1968;128:197-221.
151. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic ignorance of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000;6:686-688.
152. Lafferty KJ, Prowse SJ, Simeonovic CJ. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu Rev Immunol 1983;1:143-173.
153. Brent L. A History of Transplantation Immunology. London: Academic Press, 1997:182-338.
154. Waldmann H. Transplantation tolerance-where do we stand? Nat Med 1999;5:1245-1248.
155. Walker LSK, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2002;2:11-19.
156. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation: friend or foe? Immunity 2001;14:357-368.
157. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-1212.